Table 2.
Cohort descriptiona and association with 30-day mortality.
| Total | Survivors | 30-Day mortality | Adjusted waste | p | |
|---|---|---|---|---|---|
| Sample | 187 | 160 (85.6%) | 27 (14.4%) | ||
| Sex (male) | 90 (48.13%) | 76 (84.4%) | 14 (15.6%) | 0.67 | |
| Age (years) | 48.5 ± 20.6 | 46.37 ± 20.6 | 61.41 ± 16.04 | F = 4.39 | 0.037 |
| ASA status | |||||
| I | 31 (16.6%) | 31 (19.4%) | 0 | 2.5 | 0.01 |
| II | 71 (38%) | 64 (40%) | 7 (26%) | 4.0 | <0.001 |
| III | 55 (29.4%) | 47 (29.4%) | 8 (29.6%) | 0 | 1 |
| ≥IV | 30 (16.1%) | 18 (7.5%) | 12 (44.4%) | 7.7 | <0.001 |
| Risk situations | |||||
| Anemia | 54 (28.8%) | 34 (21.2%) | 20 (74.1%) | 5.6 | <0.001 |
| Shock | 14 (7.48%) | 5 (3.1%) | 9 (33.3%) | 5.5 | <0.001 |
| Hemodynamic instability | 18 (9.6%) | 9 (5.6%) | 9 (33.3%) | 4.5 | <0.001 |
| Cardiopathy | 21 (11.2%) | 20 (12.5%) | 1 (3.7%) | 0.3 | 0.73 |
| ARF or acute CKD | 33 (17.6%) | 17 (10.6%) | 16 (59.2%) | 6.1 | <0.001 |
| Sepsis | 24 (12.8%) | 12 (7.5%) | 12 (44.4%) | 5.3 | <0.001 |
| Metastatic neoplasia | 6 (3.2%) | 2 (1.2%) | 4 (14.8%) | 3.7 | <0.001 |
| Surgery size | |||||
| Minor | 45 (24.1%) | 42 (26.2%) | 3 (11.1%) | 1.7 | 0.09 |
| Intermediate | 81 (43.3) | 79 (49.4%) | 2 (7.4%) | 4.1 | 0.00 |
| Major | 61 (32.6%) | 39 (24.4%) | 22 (81.5%) | 5.9 | 0.00 |
| Temporal classification | |||||
| Emergency | 23 (12.3%) | 12 (7.5%) | 11 (40.7%) | 4.9 | <0.001 |
| Urgency | 86 (46%) | 72 (45%) | 14 (51.9%) | 0.7 | 0.48 |
| NU/NE | 78 (41.7%) | 76 (40.6%) | 2 (7.4%) | 2.6 | 0.001 |
| Procedure | |||||
| VLP cholecystectomy | 50 (26.7%) | 49 (30.6%) | 1 (3.7%) | 2.9 | <0.001 |
| Exploratory laparotomy | 44 (23.5%) | 23 (14.4%) | 21 (77.8%) | 7.2 | <0.001 |
| Minor GUT procedure | 23 (12.3%) | 21 (13.1%) | 2 (7.4%) | 0.8 | 0.42 |
| Appendectomy | 16 (8.5%) | 16 (10%) | 0 | 1.7 | 0.09 |
| Surgical debridement | 9 (4.8%) | 8 (5%) | 1 (3.7%) | 0.3 | 0.76 |
| Minor neurosurgery | 7 (3.7%) | 6 (3.7%) | 1 (3.7%) | 0 | <0.001 |
| Duration of surgery (h) | 2.1 ± 1.2 | 1.99 (0.99) | 2.32 (1.86) | F = 6.28 | 0.013 |
| Intraoperative bleeding | 15 (8%) | 9 (5.6%) | 6 (22.2%) | 2.9 | 0.013 |
| Reintervention | 33 (17.64%) | 23 (14.4%) | 10 (37%) | 2.9 | 0.04 |
| Time from indication to execution | |||||
| ≤12 h | 101 (54%) | 81 (50.6%) | 20 (74.1%) | 2.3 | 0.02 |
| 12–24 h | 49 (26.2%) | 47 (29.4%) | 2 (7.4%) | 2.4 | 0.02 |
| 24–48 h | 21 (11.2%) | 16 (10%) | 5 (18.5%) | 1.3 | 0.10 |
| ≥48 h | 16 (8.5%) | 16 (10%) | 0 | 1.7 | 0.09 |
| Complications (POMS) | |||||
| Pulmonary | 49 (26.2%) | 31 (19.4%) | 18 (66.7%) | 5.2 | <0.001 |
| Infectious | 68 (36.4%) | 52 (32.5%) | 16 (59.2%) | 2.7 | 0.01 |
| Renal | 23 (12.3%) | 11 (6.9%) | 12 (44.4%) | 5.5 | <0.001 |
| Gastrointestinal | 15 (8%) | 7 (4.4%) | 8 (29.6%) | 4.5 | <0.001 |
| Cardiovascular | 27 (14.4%) | 14 (8.7%) | 13 (48.1%) | 5.4 | <0.01 |
| Neurologic | 10 (5.3%) | 4 (2.5%) | 6 (22.2%) | 4.2 | <0.001 |
| Surgical wound | 17 (9.1%) | 12 (7.5%) | 5 (18.5%) | 1.8 | 0.07 |
ARF, acute renal failure; CKD, chronic kidney disease; VLP, videolaparoscopic; GUT, genitourinary tract; NU, non-urgent; NE, non-elective.
a
Data presented as mean ± SD or n (%).